Primary hyperaldosteronism differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 19: | Line 19: | ||
{{familytree | | | | | | | | | B01 | | | | | |B01=Plasma renin activity}} | {{familytree | | | | | | | | | B01 | | | | | |B01=Plasma renin activity}} | ||
{{familytree | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }} | {{familytree | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }} | ||
{{familytree | | C01 | | | | | | | | | | | |C02|C01=Normal or High (Plasma Renin/Aldosterone ratio <10|C02=Suppressed ( | {{familytree | | C01 | | | | | | | | | | | |C02|C01=Normal or High (Plasma Renin/Aldosterone ratio <10|C02=Suppressed (Plasma Renin/Aldosterone ratio >20}} | ||
{{familytree | | |!| | | | | | | | | | | | | |!| }} | {{familytree | | |!| | | | | | | | | | | | | |!| }} | ||
{{familytree | | D01 | | | | | | | | | | | |D02|D01=*Renin-secreting tumors<br>*Diuretic use<br>*Renovascular hypertension<br>*Coarctation of aorta<br>*Malignant phase hypertension|D02=Urinary aldosterone}} | {{familytree | | D01 | | | | | | | | | | | |D02|D01=*Renin-secreting tumors<br>*Diuretic use<br>*Renovascular hypertension<br>*Coarctation of aorta<br>*Malignant phase hypertension|D02=Urinary aldosterone}} | ||
| Line 26: | Line 26: | ||
{{familytree | | | | | | | | | | | | |!| | | |!| | | | |!| | }} | {{familytree | | | | | | | | | | | | |!| | | |!| | | | |!| | }} | ||
{{familytree | | | | | | | | | | | | F01 | | F02 | | | F03 |F01=Conn's syndrome (Primary aldosteronism)|F02=Profound K+ depletion|F03=• 17 alpha hydroxylase deficiency<br>• 11 beta hydroxylase deficiency<br>• Liddle's syndrome<br>• Licorice ingestion<br>• Deoxycortisone producing tumor|}} | {{familytree | | | | | | | | | | | | F01 | | F02 | | | F03 |F01=Conn's syndrome (Primary aldosteronism)|F02=Profound K+ depletion|F03=• 17 alpha hydroxylase deficiency<br>• 11 beta hydroxylase deficiency<br>• Liddle's syndrome<br>• Licorice ingestion<br>• Deoxycortisone producing tumor|}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | |!| | | | }} | |||
{{familytree | | | | | | | | | | | | | | | | | | | | | |G01|G01=Add Mineralocrticoid antagonist for 8 weeks}} | |||
{{familytree | | | |,|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|^|-|-|-|-|-|-|-|-|-|-|-|-|-|-|.}} | |||
{{familytree | | | |H01|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|-|H02|H01=BP response|H02=No BP response}} | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Revision as of 01:20, 10 July 2017
Overview
Differentiating Conn's Syndrome From Other Diseases
Conn's syndrome should be differentiated from other diseases causing hypertension and hypokalemia for example:
- Renal artery stenosis
- Cushing's syndrome
- Congenital adrenal hyperplasia (CAH)
- 17 alpha hydroxylase deficiency
- 11 beta hydroxylase deficiency
- Liddle's syndrome
- Diuretic use
- Licorice ingestion
- Renin-secreting tumors
| Hypertension and Hypokalemia | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Plasma renin activity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Normal or High (Plasma Renin/Aldosterone ratio <10 | Suppressed (Plasma Renin/Aldosterone ratio >20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| *Renin-secreting tumors *Diuretic use *Renovascular hypertension *Coarctation of aorta *Malignant phase hypertension | Urinary aldosterone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Elevated | Normal | Low | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conn's syndrome (Primary aldosteronism) | Profound K+ depletion | • 17 alpha hydroxylase deficiency • 11 beta hydroxylase deficiency • Liddle's syndrome • Licorice ingestion • Deoxycortisone producing tumor | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Add Mineralocrticoid antagonist for 8 weeks | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| BP response | No BP response | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||